| Dr Evan R Goldfischer, MD | |
|
50 Eastdale Ave N, Poughkeepsie, NY 12603 | |
| (845) 437-5000 | |
| Not Available |
| Full Name | Dr Evan R Goldfischer |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 32 Years |
| Location | 50 Eastdale Ave N, Poughkeepsie, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639274699 | NPI | - | NPPES |
| 01921273 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 2052661 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Westchester Medical Center | Valhalla, NY | Hospital |
| Vassar Brothers Medical Center | Poughkeepsie, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Medical Group Of The Hudson Valley Pc | 3072575109 | 95 |
News Archive
Cannabis Science, Inc., a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
Cholangiocarcinoma is a malignant tumor, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents. Therefore, searching for novel and effective therapeutic agents for CCA is necessary. In previous studies, several caged xanthones from G. hanburyi have been reported to be potent antiproliferatives as well as having anticancer and anti-tumor activities and they induce apoptosis in various cancer cell lines.
Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals - Clinical Gastroenterology and Hepatology and Gastroenterology - highlight important updates into treatments for these two debilitating diseases.
Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.
› Verified 1 days ago
| Entity Name | Premier Medical Group Of The Hudson Valley Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255437166 PECOS PAC ID: 3072575109 Enrollment ID: O20070301000268 |
News Archive
Cannabis Science, Inc., a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
Cholangiocarcinoma is a malignant tumor, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents. Therefore, searching for novel and effective therapeutic agents for CCA is necessary. In previous studies, several caged xanthones from G. hanburyi have been reported to be potent antiproliferatives as well as having anticancer and anti-tumor activities and they induce apoptosis in various cancer cell lines.
Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals - Clinical Gastroenterology and Hepatology and Gastroenterology - highlight important updates into treatments for these two debilitating diseases.
Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Evan R Goldfischer, MD 243 North Rd, Suite 304, Poughkeepsie, NY 12601-1172 Ph: (845) 451-7251 | Dr Evan R Goldfischer, MD 50 Eastdale Ave N, Poughkeepsie, NY 12603 Ph: (845) 437-5000 |
News Archive
Cannabis Science, Inc., a pioneering US pharmaceutical cannabis company, notes that comments by President Obama's Deputy Director of the White House Office of National Drug Control Policy, Tom McClellan, in yesterday's USA TODAY pinpoints the need for non-smoked medical cannabis products similar to those currently being developed for FDA clinical trials by Cannabis Science.
atients with relapsed or refractory follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than patients who do not receive this treatment, according to a meta-analysis of randomized trials in the February 10 online issue of the Journal of the National Cancer Institute.
Cholangiocarcinoma is a malignant tumor, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents. Therefore, searching for novel and effective therapeutic agents for CCA is necessary. In previous studies, several caged xanthones from G. hanburyi have been reported to be potent antiproliferatives as well as having anticancer and anti-tumor activities and they induce apoptosis in various cancer cell lines.
Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals - Clinical Gastroenterology and Hepatology and Gastroenterology - highlight important updates into treatments for these two debilitating diseases.
Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.
› Verified 1 days ago
Walter Roberts Parker, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Eastdale Ave N, Poughkeepsie, NY 12603 Phone: 845-437-5000 | |
Dr. Jason S Krumholtz, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Eastdale Ave N, Poughkeepsie, NY 12603 Phone: 845-437-5000 | |
Dr. Michael P Solliday, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Eastdale Ave N, Poughkeepsie, NY 12603 Phone: 845-437-5000 | |
Dr. Scott Kahn, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Eastdale Ave N, Poughkeepsie, NY 12603 Phone: 845-437-5000 Fax: 845-452-8857 | |
Dr. Mark R Libin, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1 Columbia Street, Suite 390, Poughkeepsie, NY 12601 Phone: 845-452-8730 Fax: 845-452-2406 | |
Dr. Neil John Kocher, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Eastdale Ave N, Poughkeepsie, NY 12603 Phone: 845-437-5000 |